The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day; Crinone, Merck Serono) administered during the luteal phase in term of pelvic pain reduction in patients with grade I-II endometriosis and / or endometrioma \<4 cm subjected to time intercourses or COS/IUI cycles.
Patients with grade I-II endometriosis and / or endometrioma \<4 cm subjected to time intercourses or COS/IUI cycles will be subjected to subcutaneous or vaginal progesterone for their luteal phase supplementation in time intercourses or IUI cycles. The aim of the study protocol will be to compare the efficacy of subcutaneous progesterone (25 mg / day; Pleyris, IBSA Institut Biochimique SA) with vaginal progesterone (90 mg / day; Crinone, Merck Serono) administered during the luteal phase in term of pelvic pain reduction
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
52
Magna Graecia University - Azienda Ospedaliera Pugliese Ciaccio
Catanzaro, CZ, Italy
RECRUITINGDelta VAS pain
Patients will be asked to score their menstrual pain using a VAS scale
Time frame: 7 days after the end of the menstrual period subsequent to the luteal supplementation
Analgesic use
Patients will be asked how many vials of analgesics they needed during their menstrual period
Time frame: 7 days after the end of the menstrual period subsequent to the luteal supplementation
Pregnancy rate
The percentage of pregnancies achieved in both arms will be assessed
Time frame: 30 days after the end of the menstrual period subsequent to the luteal supplementation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.